Aldosterone to Renin Ratio – A Reliable Screening Tool for Primary Aldosteronism?

Abstract

Primary aldosteronism (PA) is defined as inappropriately high and (relatively or absolutely) autonomous aldosterone secretion, which is not adequately suppressible by sodium loading. Recent evidence shows that the PA prevalence ranges from 3 to 32%. This high prevalence of PA is suggested to be the result of both more intense screening for PA and improvement of laboratory procedures. Inappropriate high aldosterone secretion is paralleled by severe target organ damage, underlining the importance for the identification of PA at an early stage. The aldosterone to renin ratio (ARR), which reflects aldosterone hypersecretion in regard to its principal trophin renin, is currently considered the most reliable tool for PA screening. Accumulating evidence, however, points to a considerable intra-individual variation of this ratio, emphasizing the importance of standardized screening procedures. In particular, laboratory methods, posture, antihypertensive medication, and dietary salt intake are significant effectors of ARR variation. Furthermore, differentiation between low-renin essential hypertension and PA is difficult and probably arbitrary. It is the purpose of the present review to issue the reliability of the ARR as a screening tool for PA. This review also provides an overview about the physiology of the renin-angiotensin-aldosterone system, highlights current laboratory methods for aldosterone and renin determination, and addresses potential influence factors on the ARR.

Key words

aldosterone to renin ratio - primary aldosteronism - adrenal adenoma - adrenal cortex

References

• 1 Conn JW. Primary aldosteronism.  J Lab Clin Med. 1955;  45 661-664
• 2 Young WF. Primary aldosteronism: renaissance of a syndrome.  Clin Endocrinol (Oxf). 2007;  66 607-618
• 3 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.  J Clin Endocrinol Metab. 2008;  93 3266-3281
• 4 Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease.  Hypertension. 2003;  42 161-165
• 5 Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Soto J, Gómez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.  J Clin Endocrinol Metab. 2000;  85 1863-1867
• 6 Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study.  J Clin Endocrinol Metab. 2004;  89 4221-4226
• 7 Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young Jr WF. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.  J Clin Endocrinol Metab. 2004;  89 1045-1050
• 8 Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension.  Hypertension. 2002;  40 892-896
• 9 Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. PAPY Study Investigators . A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.  J Am Coll Cardiol. 2006;  48 2293-2300
• 10 Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons.  N Engl J Med. 2004;  351 33-41
• 11 Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, Seki T, Demura R, Demura H. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.  Hypertens Res. 1997;  20 85-90
• 12 Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism.  JAMA. 2006;  295 2638-2645
• 13 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment.  Arch Intern Med. 2008;  168 80-85
• 14 Ritz E, Tomaschitz A. Aldosterone, a vasculotoxic agent – novel functions for an old hormone.  Nephrol Dial Transplant. 2009;  24 2302-2305
• 15 Born-Frontsberg E, Reincke M, Beuschlein F, Quinkler M. Tumor size of Conn's adenoma and comorbidities.  Horm Metab Res. 2009;  41 785-788
• 16 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.  J Am Coll Cardiol. 2005;  45 1243-1248
• 17 Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Maerz W. Plasma aldosterone levels are associated with increased cardiovascular mortality.  Eur Heart J. 2010;  ; doi:10.1093/eurheartj/ehq019
• 18 Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment.  J Hypertens. 2008;  26 613-621
• 19 Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience.  J Clin Endocrinol Metab. 2009;  94 2437-2445
• 20 Pilz S, Tomaschitz A, März W. Diagnostic procedures for primary aldosteronism.  J Lab Med. 2009;  33 ((4)) 202-209
• 21 McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.  J Clin Endocrinol Metab. 1991;  73 952-957
• 22 Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients.  J Hypertens. 2003;  21 2149-2157
• 23 Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling.  J Clin Endocrinol Metab. 2005;  90 72-78
• 24 Hirohara D, Nomura K, Okamoto T, Ujihara M, Takano K. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives.  J Clin Endocrinol Metab. 2001;  86 4292-4298
• 25 Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism.  Aust N Z J Med. 1976;  6 131-135
• 26 Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.  Arch Intern Med. 1981;  141 1589-1593
• 27 Montori VM, Young Jr. WF. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism A systematic review of the literature.  Endocrinol Metab Clin North Am. 2002;  31 619-632 xi
• 28 Pilz S, Tomaschitz A, Stepan V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Schweighofer N, Portugaller HR, Sourij H, Dobnig H, Meinitzer A, Pieber TR. Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism.  BMC Endocr Disord. 2009;  9 11
• 29 Persson PB. Renin: origin, secretion and synthesis.  J Physiol. 2003;  552 667-671
• 30 Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion.  Physiol Rev. 1990;  70 1067-1116
• 31 Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.  J Clin Invest. 2002;  110 229-238
• 32 Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review.  Nat Rev Cardiol. 2009;  6 621-630
• 33 Wagner C, Jensen BL, Kramer BK, Kurtz A. Control of the renal renin system by local factors.  Kidney Int Suppl. 1998;  67 S78-S83
• 34 Schweda F, Kurtz A. Cellular mechanism of renin release.  Acta Physiol Scand. 2004;  181 383-390
• 35 Todorov V, Muller M, Schweda F, Kurtz A. Tumor necrosis factor-alpha inhibits renin gene expression.  Am J Physiol Regul Integr Comp Physiol. 2002;  283 R1046-R1051
• 36 Vinck WJ, Fagard RH, Vlietinck R, Lijnen P. Heritability of plasma renin activity and plasma concentration of angiotensinogen and angiotensin-converting enzyme.  J Hum Hypertens. 2002;  16 417-422
• 37 Brandenberger G, Follenius M, Muzet A, Ehrhart J, Schieber JP. Ultradian oscillations in plasma renin activity: their relationships to meals and sleep stages.  J Clin Endocrinol Metab. 1985;  61 280-284
• 38 Modlinger RS, Sharif-Zadeh K, Schneider G, Gutkin M. Circadian rhythm of plasma renin activity in primary hyperaldosteronism.  J Clin Endocrinol Metab. 1976;  42 361-364
• 39 Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest.  J Appl Physiol. 2004;  96 1406-1414
• 40 Brand E, Chatelain N, Mulatero P, Féry I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L, Soubrier F. Structural analysis and evaluation of the aldosterone synthase gene in hypertension.  Hypertension. 1998;  32 198-204
• 41 Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R, Connell JM. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2.  Hypertension. 1999;  33 703-707
• 42 Lim PO, Macdonald TM, Holloway C, Friel E, Anderson NH, Dow E, Jung RT, Davies E, Fraser R, Connell JM. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio.  J Clin Endocrinol Metab. 2002;  87 4398-4402
• 43 Tanahashi H, Mune T, Takahashi Y, Isaji M, Suwa T, Morita H, Yamakita N, Yasuda K, Deguchi T, White PC, Takeda J. Association of Lys173Arg polymorphism with CYP11B2 expression in normal adrenal glands and aldosterone-producing adenomas.  J Clin Endocrinol Metab. 2005;  90 6226-6231
• 44 Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension.  Nat Rev Endocrinol. 2010;  6 83-93
• 45 Davies E, MacKenzie SM. Extra-adrenal production of corticosteroids.  Clin Exp Pharmacol Physiol. 2003;  30 437-445
• 46 Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone.  J Mol Med. 2008;  86 673-678
• 47 Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. The adrenal gland and ACTH.  Eur J Endocrinol. 1996;  135 739
• 48 Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function.  Endocr Rev. 2008;  29 133-154
• 49 Freel EM, Ingram M, Wallace AM, White A, Fraser R, Davies E, Connell JM. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects.  Clin Endocrinol (Oxf). 2008;  68 700-706
• 50 Reynolds RM, Walker BR, Phillips DI, Dennison EM, Fraser R, Mackenzie SM, Davies E, Connell JM. Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure.  Hypertension. 2009;  53 932-936
• 51 Quack I, Vonend O, Sellin L, Stegbauer J, Dekomien G, Rump LC. A tale of two patients with Mendelian hypertension.  Hypertension. 2008;  51 609-614
• 52 Reincke M, Beuschlein F, Latronico AC, Arlt W, Chrousos GP, Allolio B. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression.  Clin Endocrinol (Oxf). 1997;  46 619-626
• 53 Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JI. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man.  Circ Res. 1974;  40 69-77
• 54 Fliser D, Veldhuis JD, Dikow R, Schmidt-Gayk H, Ritz E. Effects of acute ACE inhibition on pulsatile renin and aldosterone secretion and their synchrony.  Hypertension. 1998;  32 929-934
• 55 Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways.  Physiol Rev. 2004;  84 489-539
• 56 Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis.  Horm Metab Res. 2008;  40 435-441
• 57 Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P. Increased plasma aldosterone in patients with clinical depression.  Arch Med Res. 2005;  36 544-548
• 58 Katz FH, Romfh P, Smith JA. Episodic secretion of aldosterone in supine man; relationship to cortisol.  J Clin Endocrinol Metab. 1972;  35 178-181
• 59 Cugini P, Scavo D, Cornelissen G, Lee JY, Meucci T, Halberg F. Circadian rhythms of plasma renin, aldosterone and cortisol on habitual and low dietary sodium intake.  Horm Res. 1981;  15 7-27
• 60 Ahokoski O, Virtanen A, Kairisto V, Scheinin H, Huupponen R, Irjala K. Biological day-to-day variation and reference change limits of serum cortisol and aldosterone in healthy young men on unrestricted diets.  Clin Chem. 1999;  45 1097-1099
• 61 Lieb W, Larson MG, Benjamin EJ, Yin X, Tofler GH, Selhub J, Jacques PF, Wang TJ, Vita JA, Levy D, Vasan RS, Mitchell GF. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study.  Circulation. 2009;  119 37-43
• 62 Beevers DG, Brown JJ, Cuesta V, Davies DL, Fraser R, Lebel M, Lever AF, Morton JJ, Oelkers W, Robertson JI, Schalekamp MA, Tree M. Inter-relationships between plasma angiotensin II, arterial pressure, aldosterone and exchangeable sodium in normotensive and hypertensive man.  J Steroid Biochem. 1975;  6 779-784
• 63 Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension.  Clin Endocrinol (Oxf). 2007;  67 324-334
• 64 Warnock DG. Low-renin and nonmodulating essential hypertension.  Hypertension. 1999;  34 395-397
• 65 Mulatero P, Schiavone D, Fallo F, Rabbia F, Pilon C, Chiandussi L, Pascoe L, Veglio F. CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism.  Hypertension. 2000;  35 694-698
• 66 Griffing GT, Wilson TE, Melby JC. Alterations in aldosterone secretion and metabolism in low renin hypertension.  J Clin Endocrinol Metab. 1990;  71 1454-1460
• 67 Drayer JI, Weber MA, Sealey JE, Laragh JH. Low and high renin essential hypertension: a comparison of clinical and biochemical characteristics.  Am J Med Sci. 1981;  281 135-142
• 68 Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism.  J Hypertens. 2001;  19 353-361
• 69 Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.  Ann Intern Med. 2009;  150 776-783
• 70 Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes.  Arch Intern Med. 1993;  153 2125-2129
• 71 Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill Jr Jr JR. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma.  J Clin Endocrinol Metab. 2000;  85 4526-4533
• 72 Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps.  Clin Chem. 2006;  52 1749-1755
• 73 Hartman D, Sagnella GA, Chesters CA, Macgregor GA. Direct renin assay and plasma renin activity assay compared.  Clin Chem. 2004;  50 2159-2161
• 74 Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, Ménard J. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement.  Clin Chem. 2009;  55 867-877
• 75 Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.  Mayo Clin Proc. 2001;  76 877-882
• 76 Derkx FH, de Bruin RJ, van Gool JM, van den Hoek MJ, Beerendonk CC, Rosmalen F, Haima P, Schalekamp MA. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.  Clin Chem. 1996;  42 1051-1063
• 77 Deinum J, Derkx FH, Schalekamp MA. Improved immunoradiometric assay for plasma renin.  Clin Chem. 1999;  45 847-854
• 78 Dessì-Fulgheri P, Cocco F, Glorioso N, Bandiera F, Madeddu P, Rappelli A. Immunoradiometric assay of active renin in human plasma: comparison with plasma renin activity.  Clin Exp Hypertens A. 1987;  9 1383-1390
• 79 Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states.  Trends Endocrinol Metab. 2005;  16 86-91
• 80 Sealey JE, Moon C, Laragh JH, Alderman M. Plasma prorenin: cryoactivation and relationship to renin substrate in normal subjects.  Am J Med. 1976;  61 731-738
• 81 Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.  Am J Hypertens. 2009;  22 112-121
• 82 Ismail AA, Walker PL, Cawood ML, Barth JH. Interference in immunoassay is an underestimated problem.  Ann Clin Biochem. 2002;  39 366-373
• 83 Herold DA, Fitzgerald RL. Immunoassays for testosterone in women: better than a guess?.  Clin Chem. 2003;  49 1250-1251
• 84 Turpeinen U, Hamalainen E, Stenman UH. Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry.  J Chromatogr B Analyt Technol Biomed Life Sci. 2008;  862 113-118
• 85 Ceglarek U, Kortz L, Leichtle A, Fiedler GM, Kratzsch J, Thiery J. Rapid quantification of steroid patterns in human serum by on-line solid phase extraction combined with liquid chromatography-triple quadrupole linear ion trap mass spectrometry.  Clin Chim Acta. 2009;  401 114-118
• 86 Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry.  Clin Chem. 2009;  55 1155-1162
• 87 Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y, Petersenn S, Zwermann O, Plouin PF, Reincke M, Bidlingmaier M. Saliva as a medium for aldosterone measurement in repeated sampling studies.  Steroids. 2009;  74 853-858
• 88 Fraser CG. Data on biological variation: essential prerequisites for introducing new procedures?.  Clin Chem. 1994;  40 1671-1673
• 89 Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity.  Clin Chem. 2005;  51 386-394
• 90 Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough.  Nat Clin Pract Nephrol. 2007;  3 486-492
• 91 Snoep JD, Hovens MM, Pasha SM, Frölich M, Pijl H, Tamsma JT, Huisman MV. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines.  Hypertension. 2009;  54 1136-1142
• 92 Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.  Am J Kidney Dis. 2001;  37 699-705
• 93 Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.  Clin Endocrinol (Oxf). 2002;  57 457-465
• 94 Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.  Hypertension. 2002;  40 897-902
• 95 Seiler L, Rump LC, Schulte-Mönting J, Slawik M, Borm K, Pavenstädt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication.  Eur J Endocrinol. 2004;  150 329-337
• 96 Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.  Am J Hypertens. 2005;  18 805-812
• 97 Komiya I, Yamada T, Takasu N, Asawa T, Akamine H, Yagi N, Nagasawa Y, Ohtsuka H, Miyahara Y, Sakai H, Sato A, Aizawa T. An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system.  J Hypertens. 1997;  15 65-72
• 98 Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism.  J Clin Endocrinol Metab. 2003;  88 2489-2494
• 99 Lamarre-Cliche M, de Champlain J, Lacourcière Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.  Am J Hypertens. 2005;  18 56-64
• 100 Radke KJ, Izzo Jr. JL. Seasonal variation in haemodynamics and blood pressure-regulating hormones.  J Hum Hypertens. 2009 Sep 24;  [E Pub ahead of print]
• 101 Tsunoda K, Abe K, Goto T, Yasujima M, Sato M, Omata K, Seino M, Yoshinaga K. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma.  J Clin Endocrinol Metab. 1986;  62 384-389
• 102 Fommei E, Ghione S, Ripoli A, Maffei S, Di Cecco P, Iervasi A, Turchi S. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women.  J Hum Hypertens. 2009;  23 130-135
• 103 Pizzolo F, Raffaelli R, Memmo A, Chiecchi L, Pavan C, Guarini P, Guidi GC, Franchi M, Corrocher R, Olivieri O. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism.  J Hypertens. 2010;  28 135-142
• 104 Hew-Butler T, Noakes TD, Soldin SJ, Verbalis JG. Acute changes in endocrine and fluid balance markers during high-intensity, steady-state, and prolonged endurance running: unexpected increases in oxytocin and brain natriuretic peptide during exercise.  Eur J Endocrinol. 2008;  159 729-737
• 105 Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O'Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.  Hypertension. 2007;  49 846-856
• 106 Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism.  J Renin Angiotensin Aldosterone Syst. 2001;  2 156-169
• 107 Stowasser M, Gordon RD. Primary aldosteronism – careful investigation is essential and rewarding.  Mol Cell Endocrinol. 2004;  217 33-39
• 108 Jansen PM, Boomsma F, van den Meiracker AH. Aldosterone-to-renin ratio as a screening test for primary aldosteronism--the Dutch ARRAT Study.  Neth J Med. 2008;  66 220-228
• 109 Stowasser M. Update in primary aldosteronism.  J Clin Endocrinol Metab. 2009;  94 3623-3630
• 110 Celen O, O’Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism.  Arch Surg. 1996;  131 646-650
• 111 Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA. Primary aldosteronism: factors associated with normalization of blood pressure after surgery.  Ann Intern Med. 2001;  135 258-261

1 Both authors contributed equally to the manuscript.

Correspondence